Mobile-health Network Solutions

Mobile-health Network Solutions(MNDR)股票分析

$0.983

+0.043 (+4.42%)收盤時

Loading chart…
最高
1.040
開盤
0.969
成交量加權均價
0.99
成交量
244.06K
市值
—
最低
0.940
成交金額
241.01K
企業價值/稅息折舊攤銷前利潤(TTM)
0.00

Mobile-health Network Solutions is an artificial intelligence (AI)-powered digital health platform, with operations across Southeast Asia and expanding into the United States. The Company provides telemedicine, AI-driven health tools, and virtual clinic infrastructure to empower patients and doctors worldwide. The Company's MaNaDr platform is a 360-degree healthcare ecosystem which connects users and service providers through the range of healthcare services and product offerings that can be accessed through the mobile application and website. The healthcare solutions offered on its MaNaDr platform primarily encompass: MaNaDr Mobile Application, MaNaPharma, MaNaShop/MaNaStore, and MaNaCare. It offers teleconsultation services over its MaNaDr mobile application, through online consultations provided by its in-house medical team and external doctors from its network of clinic service providers. MaNaPharma includes B2B sales to clinics and other healthcare service providers.

AI 分析 of Mobile-health Network Solutions (MNDR)

持有

Currently, Mobile-health Network Solutions (MNDR) is not a strong buy due to its significant year-to-date decline of 83.49% and a negative RSI of 48.774, indicating a lack of strong momentum. Although the stock surged 24% following an acquisition announcement, it remains a penny stock with a current price of 0.94, which is only 0.7% of its 52-week high of 32.52, suggesting substantial risk. The main risk is its negative net income of -665468 reported in Q2 2026, which raises concerns about its profitability and financial stability.

估值指標

Mobile-health Network Solutions(MNDR)目前預期本益比為 0.00,5 年平均預期本益比為 -13.23。

預期本益比

合理
5 年均值 P/E
-13.23
目前P/E
0.00
高估
23.13
低估
-49.59

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-11.33
目前EV/EBITDA
0.00
高估
26.12
低估
-48.79

預期股價營收比

合理
5 年均值 P/S
3.36
目前P/S
0.00
高估
14.72
低估
-8.01

Alphio AI 對 MNDR 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%MNDR

$1.16

情境價格

基

基準

基準 · 50%MNDR

$1.10

情境價格

悲

悲觀

悲觀 · 25%MNDR

$0.87

情境價格

事件時間軸

2026-06-26 (ET)

20:00:00

Mobile-Health Network Solutions Trading Halted, News Pending

2026-03-09 (ET)

06:20:00

Offering for Selling Shareholders

2025-07-16 (ET)

11:03:30

Mobile-health Network Solutions files $300M mixed securities shelf

2025-03-21 (ET)

17:18:54

Mobile-health Network Solutions files to sell 3.34M Class A ordinary shares

2024-12-17 (ET)

07:35:44

Mobile-health Network Solutions launches ManaSocial platform

資訊

MNDR 常見問題 —— 由 Alphio AI 解答

Mobile-health Network Solutions is an artificial intelligence (AI)-powered digital health platform, with operations across Southeast Asia and expanding into the United States. The Company provides telemedicine, AI-driven health tools, and virtual clinic infrastructure to empower patients and doctors worldwide. The Company's MaNaDr platform is a 360-degree healthcare ecosystem which connects users and service providers through the range of healthcare services and product offerings that can be accessed through the mobile application and website. The healthcare solutions offered on its MaNaDr platform primarily encompass: MaNaDr Mobile Application, MaNaPharma, MaNaShop/MaNaStore, and MaNaCare. It offers teleconsultation services over its MaNaDr mobile application, through online consultations provided by its in-house medical team and external doctors from its network of clinic service providers. MaNaPharma includes B2B sales to clinics and other healthcare service providers. It operates in the Technology sector (PREPACKAGED SOFTWARE industry).

Currently, Mobile-health Network Solutions (MNDR) is not a strong buy due to its significant year-to-date decline of 83.49% and a negative RSI of 48.774, indicating a lack of strong momentum. Although the stock surged 24% following an acquisition announcement, it remains a penny stock with a current price of 0.94, which is only 0.7% of its 52-week high of 32.52, suggesting substantial risk. The main risk is its negative net income of -665468 reported in Q2 2026, which raises concerns about its profitability and financial stability.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易